Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.56 |
| ▸ | CTSS | P25774 | 14/20 | 0.56 |
| ▸ | CTSB | P07858 | 5/20 | 0.47 |
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15259348 | 1.00 | CTSK (0.56) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL6654092 | 0.86 | CTSK (0.58) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL18762487 | 0.84 | CTSK (0.48) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL18762484 | 0.84 | CTSK (0.48) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL3263928 | 0.84 | CTSS (0.51) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL5450014 | 0.84 | CTSK (0.50) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL8185522 | 0.83 | CTSK (0.60) | CTSKCTSS | |
| SCHEMBL165350 | 0.83 | CYP2D6 (0.53) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL165351 | 0.83 | CYP2D6 (0.53) | CTSKCTSSCTSBCTSLCA1 | |
| SCHEMBL4998308 | 0.83 | CTSK (0.58) | CTSKCTSSCTSBCTSLCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063772-A1 | New compounds | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
| EP-1536790-A2 | OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | AstraZeneca AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| US-20040132726-A1 | heterocyclic compounds, e.g., 4-(5-m-Tolyl-[1,2,4]oxadiazol-3-ylmethyl)-piperazine-1-carboxylic acid ethyl ester; treatment of mGluR5 receptor-mediated disorders, particularly neurological disorders, psychiatric disorders, acute and chronic pain. | ASTRAZENECA AB AND NPS PHARMACEUTICALS, INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004014370-A2 | OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132726-A1 | heterocyclic compounds, e.g., 4-(5-m-Tolyl-[1,2,4]oxadiazol-3-ylmethyl)-piperazine-1-carboxylic acid ethyl ester; treatment of mGluR5 receptor-mediated disorders, particularly neurological disorders, psychiatric disorders, acute and chronic pain. | GRM5, GRIK5, GRM1 | CTSK 3631/4885CTSS 4295/4885CTSB 4430/4885 |
| US-20060063772-A1 | New compounds | NPY4R, RPS4X, P2RX4 | CTSK 2303/4885CTSS 2340/4885CTSB 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.